Cambrex Corp (CBM) 32.96 $CBM
Active Pharmaceutical Ingredients (API) Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating
M2 - Mon Feb 09, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/jgfvvc/active) has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015-2019" report to their offering. The API market in the US to grow at a CAGR of 7% over the period 2014-2019 Active pharmaceutical ingredients (API) are active substances that are used in the manufacture of drugs and that have pharmacological effects. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. API may be synthesized either chemically or through biotechnological methods. They are used in a wide range of therapeutic areas such as oncology and for treatment of conditions such as respiratory disorders and rheumatoid arthritis. One major trend upcoming in the market is the strong focus on the development and introduction of high-potency API. Such products are increasingly used in oncology and for the provision of targeted therapy. According to the report, one of the key drivers contributing to the growth of the API market in the US is the strong preference for generic drugs compared with innovative or branded drugs. The use of generic equivalents is preferred to innovative drugs, with countries encouraging doctors and pharmacists to prescribe such equivalents. Further, the report states that stringent regulationse one of the major challenges that the market faces. Vendors are required to comply with elaborate procedures prior to product commercialization. For instance, compliance with GMP requirements increases costs for vendors. Key Vendors - Abbott Laboratories - Aurobindo Pharma - Mylan - Teva Pharmaceutical Industries Other Prominent Vendors - Albemarle - Aptuit - BASF - Biocon - Boehringer Ingelheim - Cambrex - Cipla - Dr. Reddy's Laboratories - Hospira - Lonza Group - Novartis - Pfizer - Sigma-Aldrich - Sun Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - API Market in the US - Market Segmentation by Type of Production Process - Market Segmentation by Type of Product - Market Segmentation by Type of Players - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/jgfvvc/active
ABT: 46.09 (+0.87), CBM: 32.96 (+0.09), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Factors Moving Markets: Special Research on Exelis, Twitter, Cambrex, CME Group, and Harris
PR Newswire - Mon Feb 09, 8:30AM CST
Editor Note: For more information about this release, please scroll to bottom.
HRS: 77.73 (+0.42), CME: 93.92 (-1.39), XLS: 24.15 (+0.04), CBM: 32.96 (+0.09), TWTR: 48.50 (+0.55)
Cambrex (CBM) Worth Watching: Stock Soars 27.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 8:25AM CST
Cambrex (CBM) was a big mover last session, with shares surging roughly 28% on the day.
CBM: 32.96 (+0.09)
Stocks Slump In Closing Hour On Greek Jitters
at Investor's Business Daily - Fri Feb 06, 3:22PM CST
Stocks swooned in the last hour and a half of Friday's session as a Standard & Poor's downgrade of Greek debt weighed on the market. The Nasdaq fell 0.4%, while the S&P 500 and the Dow Jones industrial average each dropped 0.3% in the stock market...
AMBA: 50.71 (-4.46), GPRO: 45.27 (-0.02), CBM: 32.96 (+0.09), LNKD: 269.00 (+1.83), NXPI: 84.79 (-0.60)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 11:45AM CST
GSB: 3.15 (+0.11), ARCW: 6.62 (+0.23), CBM: 32.96 (+0.09), TROV: 4.99 (-0.17), HGSH: 3.05 (-0.13), RENT: 58.90 (+0.39), NKA: 1.68 (+0.13), EGAN: 3.78 (+0.08), BIOC: 1.41 (+0.22), CPPL: 28.18 (+0.39), DAC: 5.86 (-0.01), MXWL: 6.47 (+0.07), XLS: 24.15 (+0.04), PLUS: 80.17 (-0.21), EARS: 5.88 (-0.01), P: 15.44 (+0.45), ATV: 1.17 (-0.08), YELP: 47.53 (-0.10), TWTR: 48.50 (+0.55), CTRL: 13.39 (+0.10)
Cambrex (CBM) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Fri Feb 06, 7:25AM CST
CBM: 32.96 (+0.09)
Cambrex ups earnings 214% in Q4
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 6:45AM CST
CBM: 32.96 (+0.09)
Cambrex beats by $0.14, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 6:07AM CST
CBM: 32.96 (+0.09)
Cambrex Announces Expansion of Large Scale API Capacity
PR Newswire - Fri Feb 06, 6:01AM CST
Cambrex Corporation (NYSE: CBM, "Cambrex"
is pleased to announce that it has initiated the second significant expansion of its Charles City, Iowa facility in less than three years. Strong continued growth in demand for the Company's active pharmaceutical ingredient (API) contract manufacturing capabilities is driving the need for more capacity. The Company expects to invest between $45 and $50 million during 2015, including a state of the art cGMP production facility and related supporting infrastructure. This project is expected to be completed in early 2016 and is designed to allow Cambrex to quickly and efficiently further expand cGMP capacity, as future growth requires.
CBM: 32.96 (+0.09)
Cambrex Reports Fourth Quarter And Full Year 2014 Financial Results
PR Newswire - Fri Feb 06, 6:00AM CST
Cambrex Corporation (NYSE: CBM) reports results for the fourth quarter and full year ended December 31, 2014.
CBM: 32.96 (+0.09)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 4:30PM CST
HRS: 77.73 (+0.42), SIRO: 91.06 (+0.18), STRA: 62.41 (-0.74), CBM: 32.96 (+0.09), UFS: 44.99 (-0.10), ALU: 3.89 (-0.03), AXL: 24.73 (-0.22), WETF: 19.08 (+0.67), AON: 100.56 (-0.18), BECN: 28.08 (+0.64), CAE: 12.21 (+0.11), MMC: 56.31 (-0.22), MCO: 98.22 (+0.01), FLIR: 33.01 (-0.23), MSG: 78.72 (+0.53), CBOE: 63.01 (+0.84), BPL: 74.72 (+0.09), AAN: 31.35 (-0.09), DWSN: 6.89 (-0.42)
Cambrex To Announce Fourth Quarter 2014 Financial Results On February 6, 2015
PR Newswire - Wed Feb 04, 1:32PM CST
Cambrex Corporation (NYSE: CBM) announced that fourth quarter 2014 financial results will be released on Friday, February 6, 2015 before the market opens.
CBM: 32.96 (+0.09)
Cambrex appoints Samantha M. Hanley as new VP
M2 - Tue Feb 03, 5:03AM CST
Life sciences company Cambrex (NYSE:CBM) revealed on Monday that is has promoted Samantha M. Hanley to the positions of vice president, general counsel and secretary.
CBM: 32.96 (+0.09)
Ms. Samantha M. Hanley Promoted To Vice President, General Counsel and Secretary
PR Newswire - Mon Feb 02, 8:36AM CST
Cambrex Corporation (NYSE: CBM, "Cambrex" announced today that Samantha M. Hanley has been promoted to the position of Vice President, General Counsel and Secretary, reporting to Cambrex President & CEO, Steven M. Klosk. She succeeds William M. Haskel, who has decided to seek other opportunities outside of Cambrex. Mr. Haskel will remain with Cambrex through the end of February to ensure a smooth transition.
CBM: 32.96 (+0.09)
Global Active Pharmaceutical Ingredients Market 2015-2019: Key Vendors are Aurobindo Pharma, BASF, Boehringer Ingelheim, Cipla, Dr. Reddy's, Lonza and Teva Pharmaceutical Industries
M2 - Mon Dec 29, 3:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/qdgl9n/global_active) has announced the addition of the "Global Active Pharmaceutical Ingredients Market 2015-2019" report to their offering. Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. They are used in a wide range of therapeutic areas such as oncology, respiratory disorders, and rheumatoid arthritis. The analysts forecast the Global Active Pharmaceutical Ingredients market to grow at a CAGR of 7.48 percent over the period 2014-2019. This report covers the present scenario and the growth prospects of the Global Active Pharmaceutical Ingredients market during the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of active pharmaceutical ingredients by vendors in the market. The report provides the vendor landscape and a corresponding detailed analysis of the top seven vendors in the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Global Active Pharmaceutical Ingredients Market 08. Market Segmentation by Type of Production Process 09. Market Segmentation by Type of Product 10. Market Segmentation by Type of Player 11. Geographical Segmentation 12. Key Leading Countries 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AMPAC Fine Chemicals - Abbott Laboratories - Actavi - Aesica - Albemarle - Anhui Biochem United Pharmaceutical - Anuh Pharma - Aptuit - AstraZeneca - Aurobindo Pharma - BASF - Biocon - Boehringer Ingelheim - Bristol-Myers Squibb - CIRON Drugs and Pharmaceuticals - CTX Life Science - Calyx Chemicals & Pharmaceuticals - Cambrex - Cilag - Cipla - Dishman Pharmaceuticals & Chemicals - Dr. Paul Lohmann - Dr. Reddy's Laboratories - Emcure Pharmaceuticals - F. Hoffmann-La Roche - Farmabios - GlaxoSmithKline - Guilin Pharmaceutical - Hetero Drugs For more information visit http://www.researchandmarkets.com/research/qd...bal_active
ABT: 46.09 (+0.87), CBM: 32.96 (+0.09), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56)
22.2% Return Seen to Date on SmarTrend Cambrex Call (CBM)
Comtex SmarTrend(R) - Thu Dec 18, 9:54AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 2 months, Cambrex has returned 22.20% as of today's recent price of $23.53.
CBM: 32.96 (+0.09)
United States Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry Analytics 2014-2021 - Market to reach $21.2 billion by 2021
M2 - Mon Dec 15, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/b7xlml/vitamins) has announced the addition of Plunkett Research Ltd's new report "Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.) to reach $21.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - Aceto Corporation - Balchem Corp - Cambrex Corp - Mannatech Inc - Mead Johnson Nutrition Company - NBTY Inc - Schiff Nutrition International Inc - Sigma-Aldrich Corp - Synutra International, Inc. - USANA Health Sciences Inc For more information visit http://www.researchandmarkets.com/research/b7xlml/vitamins Source: Plunkett Research Ltd
ACET: 20.00 (+0.27), MJN: 101.89 (+2.32), CBM: 32.96 (+0.09), SIAL: 138.20 (+0.07), USNA: 101.37 (+0.53), SYUT: 5.29 (unch), MTEX: 23.89 (+0.69), BCPC: 58.18 (+0.84)
Uptrend Call Working As Cambrex Stock Rises 22.0% (CBM)
Comtex SmarTrend(R) - Thu Dec 11, 9:37AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 1 month, Cambrex has returned 21.99% as of today's recent price of $23.49.
CBM: 32.96 (+0.09)
Cambrex To Present At Oppenheimer 25th Annual Healthcare Conference
PR Newswire - Thu Dec 04, 12:40PM CST
Cambrex Corporation (NYSE: CBM, "Cambrex" is pleased to announce that Steven M. Klosk, President and Chief Executive Officer, will present at the Oppenheimer 25th Annual Healthcare Conference on December 11, 2014 at 8:00 a.m. EST, in New York City.
CBM: 32.96 (+0.09)
Shares of CBM Up 19.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 03, 4:58PM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 1 month, Cambrex has returned 19.86% as of today's recent price of $23.08.
CBM: 32.96 (+0.09)
Active Pharmaceutical Ingredients (API) Market in the US 2015-2019 with Abbott Laboratories, Aurobindo Pharma, Mylan & Teva Pharmaceutical Industries Dominating
M2 - Mon Feb 09, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/jgfvvc/active) has announced the addition of the "Active Pharmaceutical Ingredients (API) Market in the US 2015-2019" report to their offering. The API market in the US to grow at a CAGR of 7% over the period 2014-2019 Active pharmaceutical ingredients (API) are active substances that are used in the manufacture of drugs and that have pharmacological effects. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. API may be synthesized either chemically or through biotechnological methods. They are used in a wide range of therapeutic areas such as oncology and for treatment of conditions such as respiratory disorders and rheumatoid arthritis. One major trend upcoming in the market is the strong focus on the development and introduction of high-potency API. Such products are increasingly used in oncology and for the provision of targeted therapy. According to the report, one of the key drivers contributing to the growth of the API market in the US is the strong preference for generic drugs compared with innovative or branded drugs. The use of generic equivalents is preferred to innovative drugs, with countries encouraging doctors and pharmacists to prescribe such equivalents. Further, the report states that stringent regulationse one of the major challenges that the market faces. Vendors are required to comply with elaborate procedures prior to product commercialization. For instance, compliance with GMP requirements increases costs for vendors. Key Vendors - Abbott Laboratories - Aurobindo Pharma - Mylan - Teva Pharmaceutical Industries Other Prominent Vendors - Albemarle - Aptuit - BASF - Biocon - Boehringer Ingelheim - Cambrex - Cipla - Dr. Reddy's Laboratories - Hospira - Lonza Group - Novartis - Pfizer - Sigma-Aldrich - Sun Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - API Market in the US - Market Segmentation by Type of Production Process - Market Segmentation by Type of Product - Market Segmentation by Type of Players - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/jgfvvc/active
ABT: 46.09 (+0.87), CBM: 32.96 (+0.09), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Factors Moving Markets: Special Research on Exelis, Twitter, Cambrex, CME Group, and Harris
PR Newswire - Mon Feb 09, 8:30AM CST
Editor Note: For more information about this release, please scroll to bottom.
HRS: 77.73 (+0.42), CME: 93.92 (-1.39), XLS: 24.15 (+0.04), CBM: 32.96 (+0.09), TWTR: 48.50 (+0.55)
Cambrex (CBM) Worth Watching: Stock Soars 27.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 8:25AM CST
Cambrex (CBM) was a big mover last session, with shares surging roughly 28% on the day.
CBM: 32.96 (+0.09)
Stocks Slump In Closing Hour On Greek Jitters
at Investor's Business Daily - Fri Feb 06, 3:22PM CST
Stocks swooned in the last hour and a half of Friday's session as a Standard & Poor's downgrade of Greek debt weighed on the market. The Nasdaq fell 0.4%, while the S&P 500 and the Dow Jones industrial average each dropped 0.3% in the stock market...
AMBA: 50.71 (-4.46), GPRO: 45.27 (-0.02), CBM: 32.96 (+0.09), LNKD: 269.00 (+1.83), NXPI: 84.79 (-0.60)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 11:45AM CST
GSB: 3.15 (+0.11), ARCW: 6.62 (+0.23), CBM: 32.96 (+0.09), TROV: 4.99 (-0.17), HGSH: 3.05 (-0.13), RENT: 58.90 (+0.39), NKA: 1.68 (+0.13), EGAN: 3.78 (+0.08), BIOC: 1.41 (+0.22), CPPL: 28.18 (+0.39), DAC: 5.86 (-0.01), MXWL: 6.47 (+0.07), XLS: 24.15 (+0.04), PLUS: 80.17 (-0.21), EARS: 5.88 (-0.01), P: 15.44 (+0.45), ATV: 1.17 (-0.08), YELP: 47.53 (-0.10), TWTR: 48.50 (+0.55), CTRL: 13.39 (+0.10)
Cambrex (CBM) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Fri Feb 06, 7:25AM CST
CBM: 32.96 (+0.09)
Cambrex ups earnings 214% in Q4
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 6:45AM CST
CBM: 32.96 (+0.09)
Cambrex beats by $0.14, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Feb 06, 6:07AM CST
CBM: 32.96 (+0.09)
Cambrex Announces Expansion of Large Scale API Capacity
PR Newswire - Fri Feb 06, 6:01AM CST
Cambrex Corporation (NYSE: CBM, "Cambrex"
is pleased to announce that it has initiated the second significant expansion of its Charles City, Iowa facility in less than three years. Strong continued growth in demand for the Company's active pharmaceutical ingredient (API) contract manufacturing capabilities is driving the need for more capacity. The Company expects to invest between $45 and $50 million during 2015, including a state of the art cGMP production facility and related supporting infrastructure. This project is expected to be completed in early 2016 and is designed to allow Cambrex to quickly and efficiently further expand cGMP capacity, as future growth requires. CBM: 32.96 (+0.09)
Cambrex Reports Fourth Quarter And Full Year 2014 Financial Results
PR Newswire - Fri Feb 06, 6:00AM CST
Cambrex Corporation (NYSE: CBM) reports results for the fourth quarter and full year ended December 31, 2014.
CBM: 32.96 (+0.09)
Notable earnings before Friday’s open
Seeking Alpha - at Seeking Alpha - Thu Feb 05, 4:30PM CST
HRS: 77.73 (+0.42), SIRO: 91.06 (+0.18), STRA: 62.41 (-0.74), CBM: 32.96 (+0.09), UFS: 44.99 (-0.10), ALU: 3.89 (-0.03), AXL: 24.73 (-0.22), WETF: 19.08 (+0.67), AON: 100.56 (-0.18), BECN: 28.08 (+0.64), CAE: 12.21 (+0.11), MMC: 56.31 (-0.22), MCO: 98.22 (+0.01), FLIR: 33.01 (-0.23), MSG: 78.72 (+0.53), CBOE: 63.01 (+0.84), BPL: 74.72 (+0.09), AAN: 31.35 (-0.09), DWSN: 6.89 (-0.42)
Cambrex To Announce Fourth Quarter 2014 Financial Results On February 6, 2015
PR Newswire - Wed Feb 04, 1:32PM CST
Cambrex Corporation (NYSE: CBM) announced that fourth quarter 2014 financial results will be released on Friday, February 6, 2015 before the market opens.
CBM: 32.96 (+0.09)
Cambrex appoints Samantha M. Hanley as new VP
M2 - Tue Feb 03, 5:03AM CST
Life sciences company Cambrex (NYSE:CBM) revealed on Monday that is has promoted Samantha M. Hanley to the positions of vice president, general counsel and secretary.
CBM: 32.96 (+0.09)
Ms. Samantha M. Hanley Promoted To Vice President, General Counsel and Secretary
PR Newswire - Mon Feb 02, 8:36AM CST
Cambrex Corporation (NYSE: CBM, "Cambrex"
announced today that Samantha M. Hanley has been promoted to the position of Vice President, General Counsel and Secretary, reporting to Cambrex President & CEO, Steven M. Klosk. She succeeds William M. Haskel, who has decided to seek other opportunities outside of Cambrex. Mr. Haskel will remain with Cambrex through the end of February to ensure a smooth transition. CBM: 32.96 (+0.09)
Global Active Pharmaceutical Ingredients Market 2015-2019: Key Vendors are Aurobindo Pharma, BASF, Boehringer Ingelheim, Cipla, Dr. Reddy's, Lonza and Teva Pharmaceutical Industries
M2 - Mon Dec 29, 3:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/qdgl9n/global_active) has announced the addition of the "Global Active Pharmaceutical Ingredients Market 2015-2019" report to their offering. Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. They are used in a wide range of therapeutic areas such as oncology, respiratory disorders, and rheumatoid arthritis. The analysts forecast the Global Active Pharmaceutical Ingredients market to grow at a CAGR of 7.48 percent over the period 2014-2019. This report covers the present scenario and the growth prospects of the Global Active Pharmaceutical Ingredients market during the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of active pharmaceutical ingredients by vendors in the market. The report provides the vendor landscape and a corresponding detailed analysis of the top seven vendors in the market. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Global Active Pharmaceutical Ingredients Market 08. Market Segmentation by Type of Production Process 09. Market Segmentation by Type of Product 10. Market Segmentation by Type of Player 11. Geographical Segmentation 12. Key Leading Countries 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AMPAC Fine Chemicals - Abbott Laboratories - Actavi - Aesica - Albemarle - Anhui Biochem United Pharmaceutical - Anuh Pharma - Aptuit - AstraZeneca - Aurobindo Pharma - BASF - Biocon - Boehringer Ingelheim - Bristol-Myers Squibb - CIRON Drugs and Pharmaceuticals - CTX Life Science - Calyx Chemicals & Pharmaceuticals - Cambrex - Cilag - Cipla - Dishman Pharmaceuticals & Chemicals - Dr. Paul Lohmann - Dr. Reddy's Laboratories - Emcure Pharmaceuticals - F. Hoffmann-La Roche - Farmabios - GlaxoSmithKline - Guilin Pharmaceutical - Hetero Drugs For more information visit http://www.researchandmarkets.com/research/qd...bal_active
ABT: 46.09 (+0.87), CBM: 32.96 (+0.09), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56)
22.2% Return Seen to Date on SmarTrend Cambrex Call (CBM)
Comtex SmarTrend(R) - Thu Dec 18, 9:54AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 2 months, Cambrex has returned 22.20% as of today's recent price of $23.53.
CBM: 32.96 (+0.09)
United States Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry Analytics 2014-2021 - Market to reach $21.2 billion by 2021
M2 - Mon Dec 15, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/b7xlml/vitamins) has announced the addition of Plunkett Research Ltd's new report "Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.) to reach $21.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - Aceto Corporation - Balchem Corp - Cambrex Corp - Mannatech Inc - Mead Johnson Nutrition Company - NBTY Inc - Schiff Nutrition International Inc - Sigma-Aldrich Corp - Synutra International, Inc. - USANA Health Sciences Inc For more information visit http://www.researchandmarkets.com/research/b7xlml/vitamins Source: Plunkett Research Ltd
ACET: 20.00 (+0.27), MJN: 101.89 (+2.32), CBM: 32.96 (+0.09), SIAL: 138.20 (+0.07), USNA: 101.37 (+0.53), SYUT: 5.29 (unch), MTEX: 23.89 (+0.69), BCPC: 58.18 (+0.84)
Uptrend Call Working As Cambrex Stock Rises 22.0% (CBM)
Comtex SmarTrend(R) - Thu Dec 11, 9:37AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 1 month, Cambrex has returned 21.99% as of today's recent price of $23.49.
CBM: 32.96 (+0.09)
Cambrex To Present At Oppenheimer 25th Annual Healthcare Conference
PR Newswire - Thu Dec 04, 12:40PM CST
Cambrex Corporation (NYSE: CBM, "Cambrex"
is pleased to announce that Steven M. Klosk, President and Chief Executive Officer, will present at the Oppenheimer 25th Annual Healthcare Conference on December 11, 2014 at 8:00 a.m. EST, in New York City. CBM: 32.96 (+0.09)
Shares of CBM Up 19.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 03, 4:58PM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 1 month, Cambrex has returned 19.86% as of today's recent price of $23.08.
CBM: 32.96 (+0.09)
